Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Abt-288. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abt-288 SCHEMBL3691125 | 1.00 | HRH3 (1.00) | HRH3KCNH2 | |
| Abt-288 SCHEMBL2406947 | 1.00 | HRH3 (1.00) | HRH3KCNH2 | |
| Abt-288 SCHEMBL3048597 | 0.99 | HRH3 (0.98) | HRH3KCNH2 | |
| Abt-288 SCHEMBL3047555 | 0.98 | HRH3 (0.96) | HRH3KCNH2 | |
| Abt-288 SCHEMBL3053619 | 0.91 | HRH3 (0.83) | HRH3KCNH2 | |
| Abt-288 SCHEMBL3052867 | 0.90 | HRH3 (0.81) | HRH3KCNH2 | |
| SCHEMBL5144119 | 0.89 | HRH3 (0.79) | HRH3KCNH2 | |
| SCHEMBL2413789 | 0.89 | HRH3 (0.79) | HRH3KCNH2 | |
| SCHEMBL2410328 | 0.89 | HRH3 (0.79) | HRH3KCNH2 | |
| SCHEMBL5143942 | 0.89 | HRH3 (0.79) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | claimed |
| WO-2024191125-A1 | METHOD FOR ACTIVATING ENDOGENOUS NEURAL STEM CELLS THROUGH LOW-INTENSITY FOCUSED ULTRASOUND TREATMENT | 연세대학교 산학협력단 | 2024-09-19 | — | — | WO | claimed |
| WO-2024182465-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | ALCO THERAPEUTICS, LLC (US) | 2024-09-06 | — | — | WO | claimed |
| EP-4065097-A1 | PARTHANATOS CELL DEATH INHIBITORS FOR USE IN THE TREATMENT OF PSORIASIS | Universidad De Murcia (ES) | 2022-10-05 | — | — | EP | claimed |
| US-20080159958-A1 | DETERMINATION OF HISTAMINE-3 BIOACTIVITY | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | claimed |
| US-20260048083-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | NKMAX CO LTD (KR) | 2026-02-19 | — | — | US | disclosed |
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | disclosed |
| US-20250344963-A1 | METHODS FOR ACQUIRING AND ANALYZING NEUROMELANIN-SENSITIVE MRI | UNIV OF OTTAWA INSTITUTE OF MENTAL HEALTH RESEARCH (CA) | 2025-11-13 | — | — | US | disclosed |
| US-20250195477-A1 | DEUTERATED IDAZOXAN AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. | 2025-06-19 | — | — | US | disclosed |
| US-12208027-B2 | Combinatorial therapies including implantable damping devices and therapeutic agents for treating a condition and associated systems and methods of use | The Brain Protection Company PTY LTD (AU) | 2025-01-28 | — | — | US | disclosed |
| CN-119053573-A | Deuterated imidazole kesheng and methods of use thereof | 人类生物科学股份有限公司 | 2024-11-29 | — | — | CN | disclosed |
| WO-2024238387-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | NKMAX CO., LTD. (KR) | 2024-11-21 | — | — | WO | disclosed |
| US-8026240-B2 | Octahydro-pyrrolo[3,4-b]pyrrole N-oxides | ABBOTT LABORATORIES (US) | 2011-09-27 | — | — | US | disclosed |
| US-20100222358-A1 | OCTAHYDRO-PYRROLO[3,4-B]PYRROLE DERIVATIVES | ABBOTT LABORATORIES (US) | 2010-09-02 | — | — | US | disclosed |
| US-7728031-B2 | Octahydro-pyrrolo[3,4-b]pyrrole derivatives | ABBOTT LABORATORIES (US) | 2010-06-01 | — | — | US | disclosed |
| EP-2188288-A1 | OCTAHYDRO-PYRROLO[3,4-B]PYRROLE N-OXIDES | Abbott Laboratories (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20090105267-A1 | OCTAHYDRO-PYRROLO[3,4-B]PYRROLE N-OXIDES | ABBOTT LABORATORIES (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2009036132-A1 | OCTAHYDRO-PYRROLO[3,4-B]PYRROLE N-OXIDES | ABBOTT LABORATORIES (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20080159958-A1 | DETERMINATION OF HISTAMINE-3 BIOACTIVITY | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| US-20070232612-A1 | Octahydro-pyrrolo[3,4-b]pyrrole Derivatives | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222358-A1 | OCTAHYDRO-PYRROLO[3,4-B]PYRROLE DERIVATIVES | HRH4, HRH2, TAC3 | HRH3 4/4885KCNH2 689/4885 |
| US-20090105267-A1 | OCTAHYDRO-PYRROLO[3,4-B]PYRROLE N-OXIDES | TACR1, HTR3A, OPRM1 | HRH3 34/4885KCNH2 1067/4885 |
| US-20070232612-A1 | Octahydro-pyrrolo[3,4-b]pyrrole Derivatives | HRH4, HRH2, TAC3 | HRH3 5/4885KCNH2 697/4885 |
| US-20250195477-A1 | DEUTERATED IDAZOXAN AND METHODS OF USE THEREOF | XDH, INA, SLC6A3 | HRH3 488/4885KCNH2 2224/4885 |
| US-20260048083-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | IL2, PBK, IL2RA | HRH3 1776/4885KCNH2 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.